Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Diabetes Care
Saved in:
Main Authors: | Anantharaman, Vathsala, Rossing, Peter, Anker, Stefan D, Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M, Birkenfeld, Andreas L, McGill, Janet B, Rosas, Sylvia E, Joseph, Amer, Gebel, Martin, Roberts, Luke, Scheerer, Markus F, Bakris, George L, Agarwal, Rajiv |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
American Diabetes Association
2023
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/246027 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
by: Pitt, Bertram, et al.
Published: (2023) -
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
by: George L. Bakris, et al.
Published: (2022) -
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
by: Filippatos, Gerasimos, et al.
Published: (2022) -
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
by: Bakris, George L, et al.
Published: (2023) -
Fidelities
by: Lobo, Sandra Ataíde
Published: (2024)